

# Pamela Kearns

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8500887/pamela-kearns-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10  
papers

195  
citations

6  
h-index

10  
g-index

10  
ext. papers

243  
ext. citations

5.7  
avg. IF

2.17  
L-index

#	Paper	IF	Citations
10	Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage.. <i>JCO Global Oncology</i> , <b>2022</b> , 8, e2100266	3.7	1
9	Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 844-851	4.5	12
8	Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 812-820	12.9	9
7	Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e7-e11	4.5	3
6	Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1. <i>Experimental Hematology</i> , <b>2018</b> , 63, 52-63.e5	3.1	6
5	Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. <i>Blood</i> , <b>2015</b> , 125, 2386-96	2.2	88
4	Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1551-7	3	32
3	Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia. <i>PLoS ONE</i> , <b>2014</b> , 9, e87475	3.7	22
2	The need for proportionate regulation of clinical trials. <i>Lancet Oncology</i> , <b>2013</b> , 14, 454-5	21.7	4
1	Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. <i>Blood</i> , <b>2009</b> , 113, 117-26	2.2	18